What has changed since then
More trials Done but not completed
Register after licenced Use of oral cladribine
(More efficacy and importantly safety data)
Lower Dose Study: Not Done
More Dangerous drugs approved: Alemtuzumab
More adverse reactions &
More Lymphopenia